Health and Fitness Health and Fitness
Tue, December 13, 2011
[ Tue, Dec 13th 2011 ] - Market Wire
Sun Healthcare Group, Inc. Completes Amendment to Its Senior Secured Credit Facility
[ Tue, Dec 13th 2011 ] - Market Wire
West Announces First Quarter 2012 Dividend
[ Tue, Dec 13th 2011 ] - Market Wire
Electrochem Announces Agreement to Acquire Micro Power Electronics
[ Tue, Dec 13th 2011 ] - Market Wire
MannKind Resolves All Claims in Arbitration with Former Employee
[ Tue, Dec 13th 2011 ] - Market Wire
Amgen Presents Final Results from the Largest Pha .. ng the Safety and Efficacy of Nplate (Romiplostim
[ Tue, Dec 13th 2011 ] - Market Wire
WellPoint Donates $50,000 to Feeding America -- P .. .3 Million Associate Giving Campaign Contribution
[ Tue, Dec 13th 2011 ] - Market Wire
Kendall Law Group Investigates Synovis Life Technologies Inc.
[ Tue, Dec 13th 2011 ] - Market Wire
REVLIMID gevalueerd in combinatie met rituximab a .. patinten met onbehandelde chronische lymfocytair
[ Tue, Dec 13th 2011 ] - Market Wire
Trattamento combinato REVLIMID-Rituximab potenzia .. diagnosi affetti da Leucemia linfocitica cronica
[ Tue, Dec 13th 2011 ] - Market Wire
Final Phase II Data Evaluating REVLIMID and Ritux .. lapsed or Refractory Chronic Lymphocytic Leukemia
[ Tue, Dec 13th 2011 ] - Market Wire
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Synovis Life Technologies, Inc.
[ Tue, Dec 13th 2011 ] - Market Wire
Phase III Study Evaluating REVLIMID in Patients w .. Risk Smoldering Multiple Myeloma Presented at ASH
[ Tue, Dec 13th 2011 ] - Market Wire
The Briscoe Law Firm and Powers Taylor, LLP Inves .. ife Technologies, Inc. Concerning the Sale of SYN
[ Tue, Dec 13th 2011 ] - Market Wire
REVLIMID Evaluated in Combination with Rituximab .. Patients with Treatment-Naive Chronic Lymphocytic
[ Tue, Dec 13th 2011 ] - Market Wire
ICU Medical's Tego Needlefree Connector Proves Mo .. ve Than Traditional Central Venous Catheter Locks
[ Tue, Dec 13th 2011 ] - Market Wire
The Law Firm of Levi & Korsinsky, LLP Announces I .. reaches of Fiduciary Duty by the Board of Synovis
[ Tue, Dec 13th 2011 ] - Market Wire
Pharmacyclics Announces Updated Results for BTK I .. eatment of Relapsed or Refractory Chronic Lymphoc
[ Tue, Dec 13th 2011 ] - Market Wire
Daxor Announces That the VA Medical Center in Was .. gton, D.C. Acquires BVA-100 Blood Volume Analyzer
[ Tue, Dec 13th 2011 ] - Market Wire
Rigrodsky & Long, P.A. Announces Investigation of .. ologies, Inc.as Sale to Baxter International Inc.
[ Tue, Dec 13th 2011 ] - Market Wire
Healthways to Update 2011 Financial Guidance after Market Close on December 20
[ Tue, Dec 13th 2011 ] - Market Wire
Seattle Genetics and Millennium Report Data from .. Brentuximab Vedotin) in Front-line Hodgkin Lympho
[ Tue, Dec 13th 2011 ] - Market Wire
U.S. Physical Therapy to Present at the Oppenheimer 22nd Annual Healthcare Conference
[ Tue, Dec 13th 2011 ] - Market Wire
St. Jude Medical Announces First Implant in Europ .. Studying Portico Transcatheter Aortic Heart Valve
[ Tue, Dec 13th 2011 ] - Market Wire
Die Europische Kommission erteilt Astellas Pharma .. zulassung zur Verwendung von DIFICLIRa" in der EU
[ Tue, Dec 13th 2011 ] - Market Wire
La Comisin Europea concede la autorizacin de mark .. Astellas Pharma Europe Ltd., para su uso en la UE
[ Tue, Dec 13th 2011 ] - Market Wire
PhotoMedex and Radiancy Complete Merger
[ Tue, Dec 13th 2011 ] - Market Wire
Bio-Path Holdingsa Initial Phase I Data in Leukem .. s That Its Neutral Lipid Delivery Technology Anti
[ Tue, Dec 13th 2011 ] - Market Wire
Thera Maxa" Cold and Flu Debuts in Times Square D .. ring the Height of the 2011 / 2012 Holiday Season
[ Tue, Dec 13th 2011 ] - Market Wire
Direction of Market Influences - Report Highlight .. uestcor Pharmaceuticals, Inc. and Perrigo Company
[ Tue, Dec 13th 2011 ] - Market Wire
Direction of Market Influences - Report Highlight .. ceutical Industries Ltd (ADR) and Sanofi SA (ADR)

Direction of Market Influences - Report Highlights Teva Pharmaceutical Industries Ltd (ADR) and Sanofi SA (ADR)


Published on 2011-12-13 06:05:47 - Market Wire
  Print publication without navigation


December 13, 2011 09:00 ET

Direction of Market Influences - Report Highlights Teva Pharmaceutical Industries Ltd (ADR) and Sanofi SA (ADR)

NEW YORK, NY--(Marketwire - Dec 13, 2011) - Today, [ www.BrightonMarkets.com ] announced new reports highlighting Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ: [ TEVA ]) and Sanofi SA (ADR) (NYSE: [ SNY ]). Gain market insight with full analysis and research downloads available at [ www.BrightonMarkets.com/index.php?coa=TEVA&cob=SNY ].

Upcoming macro-economic 'tides of influence' are buoyed by crisis both home and abroad. Spanish and Italian yields continue to climb as efforts by the European Central Bank have stopped short of establishing sovereign bond guarantees for any one country. The result is historic yields and a grave concern for the solvency of interbank lending. Markets were drawn to concerns over domestic policy stalemates producing downgrade risks. Despite the situation, there continues to be unique value and opportunity found within careful discretion.

Brighton Markets is releasing new coverage on Teva Pharmaceutical Industries Ltd (ADR) for its current position within the healthcare industry. Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. The full research report on Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ: [ TEVA ]) is available here: [ www.BrightonMarkets.com/index.php?coa=TEVA ].

Brighton Markets has released research on Sanofi SA (ADR) for its changing role within the healthcare industry. Sanofi, formerly Sanofi-Aventis, is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. The full research report on Sanofi SA (ADR) (NYSE: [ SNY ]) is available here: [ www.BrightonMarkets.com/index.php?cob=SNY ].

About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.


Contributing Sources